In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: AI design antibody for start-ups required by open call for participants «Science and companies
AI design antibody for start-ups required by open call for participants «Science and companies
Jioforme
The International Consortium is seeking a team of scientists to use algorithms to design new therapeutic antibodies and to set up and fund start-ups. AION Lab, A coalition of pharmaceutical and technology companies in Israel, Europe, and the United States, and BioMed X, The German Institute of Biomedical Sciences, which connects the academic lab and the industry, sponsors a crowdsourcing…
Visit: AI-Designed Antibodies for Start-Up Sought in Open Call
AI-Designed Antibodies for Start-Up Sought in Open Call
Science & Enterprise
An international consortium is seeking teams of scientists using algorithms to design new therapeutic antibodies, to form and fund a start-up company. AION Labs, a coalition of Israeli, European, and American pharmaceutical and technology companies, and BioMed X, a biomedical research institute in Germany connecting academic labs to industry, are sponsoring the crowd-sourcing competition.
Visit: Global Roundup: Newly-Launched AION Forms Startup in Israel
Global Roundup: Newly-Launched AION Forms Startup in Israel
BioSpace
Less than one week after the launch of Amazon and big pharma-backed AION Labs, the AI-focused organization has partnered with Germany’s BioMedX to identify biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
Visit: Amazon’s freshly launched innovation hub to use AI in antibody design
Amazon’s freshly launched innovation hub to use AI in antibody design
Becker's Health It
AION Labs, the artificial intelligence innovation hub backed by Amazon Web Services and other leading pharmaceutical companies, is seeking to use AI to find antibodies.
Visit: Coalition of pharma and tech leaders launches to improve drug development with AI
Coalition of pharma and tech leaders launches to improve drug development with AI
European Pharmaceutical Manufacturer
A new alliance consisting of pharmaceutical companies and investment organisations has officially launched to spearhead the adoption of artificial intelligence (AI) technologies to help solve drug discovery and development challenges.
Visit: Four big pharma companies team up in AI initiative focused on drug R&D
Four big pharma companies team up in AI initiative focused on drug R&D
MedCity News
A new startup initiative in Israel aims to create and invest in startups that use artificial intelligence to address challenges in drug discovery and development. Called AION Labs, this innovation lab stems from an economic development effort from the Israeli government and will have contributions from AstraZeneca, Merck, Pfizer and Teva Pharmaceutical.
Visit: AstraZeneca, Merck KGaA, Pfizer, and Teva Team up with Tech and Investment Leaders to Launch New Biotech Innovation Lab
AstraZeneca, Merck KGaA, Pfizer, and Teva Team up with Tech and Investment Leaders to Launch New Biotech Innovation Lab
BioPharm International
AION Labs will be a first-of-its-kind AI/pharma and computational biology innovation lab aimed at spearheading the adoption of AI technologies and computational science.
Visit: Amazon and big pharma unite to propel AI innovation in therapeutics
Amazon and big pharma unite to propel AI innovation in therapeutics
Pharma Live
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovative space that will allow drug developers to harness artificial intelligence technologies and computational science to solve therapeutic challenges.
Visit: AstraZeneca, Merck KGaA, Pfizer, and Teva Team up with Tech and Investment Leaders to Launch New Biotech Innovation Lab
AstraZeneca, Merck KGaA, Pfizer, and Teva Team up with Tech and Investment Leaders to Launch New Biotech Innovation Lab
PharmTech
AION Labs will be a first-of-its-kind AI/pharma and computational biology innovation lab aimed at spearheading the adoption of AI technologies and computational science.
Visit: Amazon and Big Pharma Unite to Propel AI Innovation in Therapeutics
Amazon and Big Pharma Unite to Propel AI Innovation in Therapeutics
BioSpace
Four leading pharmaceutical companies partnered with Amazon Web Services and Israel Biotech Fund to launch AION Labs, an innovative space that will allow drug developers to harness artificial intelligence technologies and computational science to solve therapeutic challenges.
Visit: AWS and pharma heavyweights join forces on AI-based drug discovery lab
AWS and pharma heavyweights join forces on AI-based drug discovery lab
Drug Discovery & Development
The goal of using artificial intelligence to transform drug discovery and development may not be novel. But a new alliance is unique in both the stature of companies belonging to it and its choice of an innovation model.
Visit: AWS and pharma heavyweights join forces on AI-based drug discovery lab
AWS and pharma heavyweights join forces on AI-based drug discovery lab
Medical Design Sourcing
The goal of using AI to transform drug discovery and development may not be novel. But a recent alliance is unique in both the stature of companies belonging to it and its choice of an innovation model.
Visit: New innovation lab brings together pharma, biotech giants for AI therapeutics
New innovation lab brings together pharma, biotech giants for AI therapeutics
Times of Israel
Pfizer, Merck, Teva, Amazon form consortium that runs AION Labs, an Israeli facility that will focus on harnessing artificial intelligence in drug development
Visit: Big Pharma companies join hands with Amazon on new Israel-based AI incubator
Big Pharma companies join hands with Amazon on new Israel-based AI incubator
Endpoints News
What do Merck, Pfizer, AstraZeneca and Teva have in common with Amazon? As of Wednesday, they’re all joining forces with the Israel Biotech Fund to launch a new incubator for startups walking the line between AI and drug development — and they’re gearing up to make some big investments.
Visit: Eine Gemeinschaft der Willigen – Standortakteure aus Heidelberg im Gespräch
Eine Gemeinschaft der Willigen – Standortakteure aus Heidelberg im Gespräch
GoingPublic.de
Die Plattform Life Sciences fĂĽhrte eine Gesprächsrunde mit den wichtigen Vertretern dieser neuen Entwicklungen in der Rhein-Neckar-Region. Unter dem Fokusthema „Translation“ haben sich dazu hybrid getroffen: Dr. Julia Schaft (BioRN), Dr. Christian Tidona (BioMed X), Dr. Johannes FrĂĽhauf (BioLabs, LabCentral), Dr. Siegfried Bialojan (ehemaliger EY-Experte Life Sciences), Dr. Thomas Hanke (Evotec), Dr. Friedrich Reinhard (Evotec; „Expert in Residence“ beLAB2122 in…
Visit: Wie in Deutschland mehr Unternehmen wie BioNTech entstehen können
Wie in Deutschland mehr Unternehmen wie BioNTech entstehen können
Frankfurter Allgemeine Zeitung
Der Impfstoffhersteller BioNTech ist ein glanzvolles Beispiel für eine Ausgründung aus der Hochschule. In Deutschland wird viel geforscht, aber kaum gegründet. Wie kann das öfter gelingen?
Visit: BioMed X and Janssen Start Up Research Programs in Autoimmunity and Drug Delivery
BioMed X and Janssen Start Up Research Programs in Autoimmunity and Drug Delivery
BioPharm
BioMed X has partnered with Janssen to start two new research programs for autoimmune diseases and drug delivery.
Visit: Professionelle Translation in Heidelberg – Das BioMed X Institut
Professionelle Translation in Heidelberg – Das BioMed X Institut
Deutsche Biotechnologietage 2021
rotz des technologischen Fortschritts in der medizinischen Grundlagenforschung und des stetig wachsenden Wissens ĂĽber menschliche Krankheiten, ist die Translation von Forschungsergebnissen in therapeutische Fortschritte immer noch ineffizient.
Visit: BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research
BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research
Pharma Advancement
German independent research institute BioMed X has initiated two new research projects with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration aims to address two challenging new research areas.
Visit: BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research
BioMed X, Janssen Begin Autoimmunity and Drug Delivery Research
Contract Pharma
New research groups, PTA and TMI, aim to combat chronic inflammatory diseases and develop oral delivery of macromolar therapeutics.
Visit: BioMed X Institute to launch autoimmunity and drug delivery research programs
BioMed X Institute to launch autoimmunity and drug delivery research programs
BioSpectrum Asia Edition
New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier in collaboration with Janssen.